ArticleJAAD case reports2019
Recalcitrant prurigo nodularis treated successfully with dupilumab.
Article in JAAD case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy and Safety of Conventional and Biologic Therapies in Prurigo Nodularis: A Systematic Review and Meta-Analysis.International journal of dermatology · 2026Pooled it
- Dupilumab in Inflammatory Skin Diseases: A Systematic Review.Biomolecules · 2023Pooled it
- Dupilumab for the treatment of prurigo nodularis: A systematic review.Frontiers in immunology · 2023Pooled it
- Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics.International journal of molecular sciences · 2024Review
- Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments.Dermatology and therapy · 2022Review
- Dupilumab treatment for cholestatic pruritus.Dermatologic therapy · 2022Article
- Short communication: Comments on hair disorders associated with dupilumab based on VigiBase.PloS one · 2022Article
- Immunotargets and Therapy for Prurigo Nodularis.ImmunoTargets and therapy · 2022Review
- Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune Polarization.The Journal of investigative dermatology · 2021Article
- Emerging Therapeutic Options for Chronic Pruritus.American journal of clinical dermatology · 2020Review
- Analysis of 325 Patients with Chronic Nodular Prurigo: Clinics, Burden of Disease and Course of Treatment.Acta dermato-venereologica · 2020Article
- Article
- A New Generation of Treatments for Itch.Acta dermato-venereologica · 2020Review
- Learning From Success and Failure: Biologics for Non-approved Skin Diseases.Frontiers in immunology · 2019Review
- Recalcitrant Prurigo Nodularis Successfully Treated with Dupilumab.Indian dermatology online journalArticle
- Prurigo: review of its pathogenesis, diagnosis, and treatment.Anais brasileiros de dermatologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.